Low-Value CareNCT07166107
EVOLV-Rx VA: Evaluating Opportunities to Decrease Low-Value Prescribing in Community Living Centers
A study testing EVOLV-Rx dashboard in people with Low-Value Care, run by VA Office of Research and Development at 3 sites in United States.
Trial summary
The investigators developed EVOLV-Rx (Evaluating Opportunities to Decrease Low-Value Prescribing), a novel clinical support tool to detect 18 evidence-based and clinically useful low-value prescribing practices in older adults. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Low-Value Care
- What is being tested?
- EVOLV-Rx dashboard
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,161 participants
- Where
- 3 sitesUnited States
- Study dates
- 1 Oct 2026to 31 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Veterans admitted to a participating VISN 4 Community Living Center (CLC) at the time of the required medication review
Who cannot join
- Veterans receiving hospice care, as the discontinuation of medications in EVOLV-Rx (e.g., benzodiazepines) may result in undue discomfort During both the usual care and intervention period of the study, the study coordinator will query the EVOLV-Rx dashboard weekly
- The coordinator will ensure the presence of inclusion/exclusion criteria via chart review and using the EVOLV-Rx dashboard, they will then flag the patient if they are receiving hospice care and should be excluded from the study
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States3 sites
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Philadelphia, Pennsylvania, 19104-4551
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
Pittsburgh, Pennsylvania, 15240
Wilkes-Barre VA Medical Center, Wilkes-Barre, PA
Wilkes-Barre, Pennsylvania, 18711
About this study
The investigators developed EVOLV-Rx (Evaluating Opportunities to Decrease Low-Value Prescribing), a novel clinical support tool to detect 18 evidence-based and clinically useful low-value prescribing practices in older adults. The objective is to conduct a hybrid study to assess the effectiveness and implementation of an EVOLV-Rx-based intervention to reduce LVP among older Veterans who reside in CLCs in VISN 4.
In Aim 1, the investigators will conduct focus groups of VISN 4 CLC leaders, clinicians, Veterans, and family caregivers, where the investigators will characterize the patient, clinician, and CLC-level barriers to and facilitators of implementation; and identify and tailor strategies to optimize the intervention's adoption and implementation. In Aim 2, the investigators will conduct a hybrid type 2 effectiveness implementation trial to compare the intervention to usual care, using a stepped wedge design in five VISN 4 CLCs. The primary effectiveness outcome is the count of low-value prescribing practices per 100 Veterans. In Aim 3, the investigators will conduct an embedded process evaluation to study implementation processes, their impact on outcomes, and iteratively improve the implementation of the intervention. The investigators will also conduct semi-structured interviews of clinicians, Veterans, and family caregivers to characterize the appropriateness, feasibility, acceptability, and perceived effectiveness of the intervention and implementation strategies employed.
Read the detailed description
Background: More than half of Veterans aged 65 years who reside in Community Living Centers (CLCs) are subject to low-value prescribing, placing them at increased risk of adverse drug events, hospitalization, and death. CLCs represent an ideal setting to safely reduce low-value prescribing; however, no intervention to broadly reduce low-value prescribing has been successfully integrated into routine care or implemented at scale across CLCs. In response, the investigators developed EVOLV-Rx (Evaluating Opportunities to Decrease Low-Value Prescribing), a novel clinical support tool to detect 18 evidence-based and clinically useful low-value prescribing practices in older adults per an expert Delphi panel and further informed by patient, caregiver, and clinician input.
Significance: The objective is to conduct a hybrid study to assess the effectiveness and implementation of an EVOLV-Rx-based intervention to reduce LVP among older Veterans who reside in CLCs in VISN 4. This study will support VA's evolution as a learning healthcare system and is aligned with VA's key strategic healthcare priority of becoming the most age-friendly healthcare system in the United States. It also aligns with two VA HSR topic areas of interest, including improving healthcare quality and value and long-term care and aging. Innovation \& Impact: EVOLV-Rx is a novel tool to detect low-value prescribing. Its unique characteristics and automated application will enable pharmacists to provide detailed recommendations to clinicians to prioritize medications for deprescribing with high clinical impact and that may be acceptably deprescribed from the perspective of patients and caregivers. EVOLV-Rx represents a substantial departure from the status quo, and its use will enhance deprescribing in CLCs and overcome several previously described implementation barriers.
Specific Aims: 1) To finalize the adaptable elements of, and implementation playbook for, the EVOLV-Rx intervention to reduce low-value prescribing for older Veterans residing in CLCs, 2) To assess the effectiveness of the EVOLV-Rx intervention to reduce low-value prescribing, 3) To evaluate and iteratively improve the implementation of the EVOLV-Rx intervention.
Methodology: Using the Theradoc clinical support platform, the intervention is an electronic EVOLV-Rx dashboard used by pharmacists to provide deprescribing recommendations to clinicians to reduce LVP as part of each Veteran's required medication review. The intervention will be translated into clinical practice in VISN 4 CLCs using a playbook of core implementation strategies previously employed in VA and additional strategies determined by key shareholders to address specific implementation barriers identified as part of the study. In Aim 1, the investigators will conduct focus groups of VISN 4 CLC leaders, clinicians, Veterans, and family caregivers, where the investigators will characterize the patient, clinician, and CLC-level barriers to and facilitators of implementation; and identify and tailor strategies to optimize the intervention's adoption and implementation. In Aim 2, the investigators will conduct a hybrid type 2 effectiveness implementation trial to compare the intervention to usual care, using a stepped wedge design in five VISN 4 CLCs. The primary effectiveness outcome is the count of low-value prescribing practices per 100 Veterans. In Aim 3, the investigators will conduct an embedded process evaluation to study implementation processes, their impact on outcomes, and iteratively improve the implementation of the intervention. The investigators will also conduct semi-structured interviews of clinicians, Veterans, and family caregivers to characterize the appropriateness, feasibility, acceptability, and perceived effectiveness of the intervention and implementation strategies employed.
Next Steps/Implementation: Leveraging VA infrastructure, the commitment of the investigators' operational partners, and the deep expertise of the research team, this proposal will result in a scalable intervention and accompanying implementation playbook to reduce low-value prescribing among Veterans receiving care in CLCs. It will also inform its deployment as a national multi-site trial to further evaluate and optimize its implementation throughout VA.
- Conditions
- Low-Value Care
- Being tested
- EVOLV-Rx dashboard
- Keywords
- Nursing Homes, Inappropriate Prescribing
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EVOLV-Rx dashboardOther
Using the TheraDoc® platform, the investigators will deploy a custom-designed EVOLV-Rx dashboard that incorporates all 18 components of the EVOLV-Rx metric. [Within TheraDoc®, the dashboard will display an automated report in the form of a patient list that includes the names, locations, and specific LVP practices to which Veterans under their care are subject. Pharmacists will then query specific patients on the list as part of their required medication review. The dashboard will provide detailed clinical decision support by identifying the specific EVOLV-Rx LVP criteria met by each flagged medication and provide access to the patient's full medication list, problem list, and laboratory or testing data contained within VISTA.] Pharmacists may use the EVOLV-Rx dashboard to track Veterans' receipt of LVP practices and quickly document actions related to the intervention, such as patient and family caregiver engagement, deprescribing LVP practices, or any other medications discontinued.
| Study group | Role | What they receive |
|---|---|---|
| Stepped Wedge | Experimental | As part of the Stepped Wedge design, each CLC serves as its own control rather than sites being allocated to distinct control and intervention arms. All sites will receive the intervention. Receives: Other: EVOLV-Rx dashboard |
What is being measured
The primary outcome is the main question the study is designed to answer.
Count of Low-Value Practices (LVP) per 100 Veterans as per the EVOLV-rx metric
The primary effectiveness outcome is the count of LVP practices per 100 Veterans as per the EVOLV-Rx metric, which the investigators will consistently assess monthly from the start of the pre-implementation usual care phase through quarter 10. Data on LVP will be obtained from the VA Corporate Data Warehouse (CDW), including BCMA data, to fully capture Veterans' duration of medication use and pertinent diagnoses incorporated in the EVOLV-Rx criteria. A low-value medication will be characterized as discontinued if its discontinuation is sustained for 7 days, as this duration is unlikely to represent a temporary discontinuation of the medication. As per RE-AIM, maintenance will be determined via the assessment of the primary effectiveness outcomes at 6 and 12 months after the start of the intervention in each step of Community Living Centers (CLCs).
Measured: Baseline (starting an average of one year prior to implementation of intervention) through study completion, average time frame of 3.25 years of observation
Secondary outcomes (5)
Average Count of Long-term medications
Meds used for 28+ days prior to or during Community Living Centers (CLCs) admission
Measured: Baseline (starting an average of one year prior to implementation of intervention) through study completion, average time frame of 3.25 years of observation
Proportion of Veterans with Polypharmacy and hyperpolypharmacy
Polypharmacy (5+ drugs), Hyperpolypharmacy (10+ drugs)
Measured: Baseline (starting an average of one year prior to implementation of intervention) through study completion, average time frame of 3.25 years of observation
Proportion of Veterans with Adverse drug reactions
All VA emergency department (ED)/hospital transfers will be evaluated quarterly for potential Adverse Drug Reactions (ADR) via the Naranjo algorithm, which will be applied via Electronic Health Record (EHR) review. The Naranjo algorithm is a 10-point questionnaire to determine whether a suspected ADR is due to a drug rather than other factors.
Measured: Baseline (starting an average of one year prior to implementation of intervention) through study completion, average time frame of 3.25 years of observation
Proportion of Veterans with Adverse drug withdrawal events
The Naranjo algorithm may also be applied to assess for adverse drug withdrawal events occurring in the period after medication withdrawal.
Measured: Baseline (starting an average of one year prior to implementation of intervention) through study completion, average time frame of 3.25 years of observation
Average Count of emergency department (ED) visits/hospitalizations
As Community Living Centers (CLCs) residents may be transferred to the emergency department (ED) or hospitalized at a non-VA facility, the investigators will query both Corporate Data Warehouse (CDW) and Medicare Data available through VIREC to assess the count of ED visits and hospitalizations. Count and review of ED visits/hospitalizations will be assessed retrospectively, given the delay in the availability of Medicare data.
Measured: Baseline (starting an average of one year prior to implementation of intervention) through study completion, average time frame of 3.25 years of observation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Sep 2025
- Study start1 Oct 2026
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Low-Value CareStudies of the same condition, open and under way.
- More trials run by VA Office of Research and DevelopmentThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Sequential
- Model description
- In Aim 2, the investigators will conduct a randomized hybrid type 2 effectiveness implementation study applying a stepped wedge design to compare the EVOLV-Rx intervention to usual care. In the stepped wedge design, each CLC serves as its own control rather than sites being allocated to distinct control and intervention arms. This will enable all participating CLCs to receive the intervention, as is the desire of the operational partners in VISN 4 and will enhance the power to detect differences in outcomes relative to a traditional cluster randomized design. The stepped wedge design also allows for a sequential rollout of the intervention at each CLC. (Aims 1 and 3 are qualitative, and do not involve any intervention model).
- Masking
- None (open label)
- Enrolment
- 1,161 participants (estimated)
Sponsor and investigators
- Lead sponsor
- VA Office of Research and Development
- Sponsor type
- US federal agency
- Responsible party
- Sponsor
- Investigators
- Thomas R Radomski, MD MS, Principal investigator, VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07166107
- Sponsor's protocol ID
- IIR 23-132
- Other IDs
- 1I01HX003849
- Status last verified
- Oct 2026
- First submitted
- 2 Sep 2025
- Last updated
- 14 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Burke RE, Hutchins F, Heintz J, Patel SR, Appel S, Norman J, Gupta A, Rose L, Werner RM. Size of the Financial Incentives in Medicare's Skilled Nursing Facility Value-Based Purchasing Program. JAMA Netw Open. 2025 Sep 2;8(9):e2533369. doi: 10.1001/jamanetworkopen.2025.33369.
PubMed 40991286Rose L, Wagner TH. The Future of the VA-The Privatization Debate. JAMA Health Forum. 2025 Sep 5;6(9):e253183. doi: 10.1001/jamahealthforum.2025.3183.
PubMed 40971164
Study at a glance
From the registry record, last updated by the sponsor on 14 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- EVOLV-Rx VA: Evaluating Opportunities to Decrease Low-Value Prescribing in Community Living Centers
- ClinicalTrials.gov ID
- NCT07166107
- Acronym / sponsor ID
- IIR 23-132
- Conditions
- Low-Value Care
- Keywords
- Nursing Homes, Inappropriate Prescribing
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 1,161 participants (estimated)
- Lead sponsor
- VA Office of Research and DevelopmentUS federal agency
- Study start
- 1 Oct 2026 (actual)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2028 (estimated)
- First posted
- 10 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators developed EVOLV-Rx (Evaluating Opportunities to Decrease Low-Value Prescribing), a novel clinical support tool to detect 18 evidence-based and clinically useful low-value prescribing practices in older adults. The objective is to conduct a hybrid study to assess the effectiveness and implementation of an EVOLV-Rx-based intervention to reduce LVP among older Veterans who reside in CLCs in VISN 4.
In Aim 1, the investigators will conduct focus groups of VISN 4 CLC leaders, clinicians, Veterans, and family caregivers, where the investigators will characterize the patient, clinician, and CLC-level barriers to and facilitators of implementation; and identify and tailor strategies to optimize the intervention's adoption and implementation. In Aim 2, the investigators will conduct a hybrid type 2 effectiveness implementation trial to compare the intervention to usual care, using a stepped wedge design in five VISN 4 CLCs. The primary effectiveness outcome is the count of low-value prescribing practices per 100 Veterans. In Aim 3, the investigators will conduct an embedded process evaluation to study implementation processes, their impact on outcomes, and iteratively improve the implementation of the intervention. The investigators will also conduct semi-structured interviews of clinicians, Veterans, and family caregivers to characterize the appropriateness, feasibility, acceptability, and perceived effectiveness of the intervention and implementation strategies employed.
Detailed description
Background: More than half of Veterans aged 65 years who reside in Community Living Centers (CLCs) are subject to low-value prescribing, placing them at increased risk of adverse drug events, hospitalization, and death. CLCs represent an ideal setting to safely reduce low-value prescribing; however, no intervention to broadly reduce low-value prescribing has been successfully integrated into routine care or implemented at scale across CLCs. In response, the investigators developed EVOLV-Rx (Evaluating Opportunities to Decrease Low-Value Prescribing), a novel clinical support tool to detect 18 evidence-based and clinically useful low-value prescribing practices in older adults per an expert Delphi panel and further informed by patient, caregiver, and clinician input.
Significance: The objective is to conduct a hybrid study to assess the effectiveness and implementation of an EVOLV-Rx-based intervention to reduce LVP among older Veterans who reside in CLCs in VISN 4. This study will support VA's evolution as a learning healthcare system and is aligned with VA's key strategic healthcare priority of becoming the most age-friendly healthcare system in the United States. It also aligns with two VA HSR topic areas of interest, including improving healthcare quality and value and long-term care and aging. Innovation \& Impact: EVOLV-Rx is a novel tool to detect low-value prescribing. Its unique characteristics and automated application will enable pharmacists to provide detailed recommendations to clinicians to prioritize medications for deprescribing with high clinical impact and that may be acceptably deprescribed from the perspective of patients and caregivers. EVOLV-Rx represents a substantial departure from the status quo, and its use will enhance deprescribing in CLCs and overcome several previously described implementation barriers.
Specific Aims: 1) To finalize the adaptable elements of, and implementation playbook for, the EVOLV-Rx intervention to reduce low-value prescribing for older Veterans residing in CLCs, 2) To assess the effectiveness of the EVOLV-Rx intervention to reduce low-value prescribing, 3) To evaluate and iteratively improve the implementation of the EVOLV-Rx intervention.
Methodology: Using the Theradoc clinical support platform, the intervention is an electronic EVOLV-Rx dashboard used by pharmacists to provide deprescribing recommendations to clinicians to reduce LVP as part of each Veteran's required medication review. The intervention will be translated into clinical practice in VISN 4 CLCs using a playbook of core implementation strategies previously employed in VA and additional strategies determined by key shareholders to address specific implementation barriers identified as part of the study. In Aim 1, the investigators will conduct focus groups of VISN 4 CLC leaders, clinicians, Veterans, and family caregivers, where the investigators will characterize the patient, clinician, and CLC-level barriers to and facilitators of implementation; and identify and tailor strategies to optimize the intervention's adoption and implementation. In Aim 2, the investigators will conduct a hybrid type 2 effectiveness implementation trial to compare the intervention to usual care, using a stepped wedge design in five VISN 4 CLCs. The primary effectiveness outcome is the count of low-value prescribing practices per 100 Veterans. In Aim 3, the investigators will conduct an embedded process evaluation to study implementation processes, their impact on outcomes, and iteratively improve the implementation of the intervention. The investigators will also conduct semi-structured interviews of clinicians, Veterans, and family caregivers to characterize the appropriateness, feasibility, acceptability, and perceived effectiveness of the intervention and implementation strategies employed.
Next Steps/Implementation: Leveraging VA infrastructure, the commitment of the investigators' operational partners, and the deep expertise of the research team, this proposal will result in a scalable intervention and accompanying implementation playbook to reduce low-value prescribing among Veterans receiving care in CLCs. It will also inform its deployment as a national multi-site trial to further evaluate and optimize its implementation throughout VA.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- In Aim 2, the investigators will conduct a randomized hybrid type 2 effectiveness implementation study applying a stepped wedge design to compare the EVOLV-Rx intervention to usual care. In the stepped wedge design, each CLC serves as its own control rather than sites being allocated to distinct control and intervention arms. This will enable all participating CLCs to receive the intervention, as is the desire of the operational partners in VISN 4 and will enhance the power to detect differences in outcomes relative to a traditional cluster randomized design. The stepped wedge design also allows for a sequential rollout of the intervention at each CLC. (Aims 1 and 3 are qualitative, and do not involve any intervention model).
| Arm | Type | Receives |
|---|---|---|
| Stepped Wedge | Experimental | Other: EVOLV-Rx dashboardAs part of the Stepped Wedge design, each CLC serves as its own control rather than sites being allocated to distinct control and intervention arms. All sites will receive the intervention. |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (1 listed)
- Veterans admitted to a participating VISN 4 Community Living Center (CLC) at the time of the required medication review
Key exclusion criteria (2 listed)
- Veterans receiving hospice care, as the discontinuation of medications in EVOLV-Rx (e.g., benzodiazepines) may result in undue discomfort During both the usual care and intervention period of the study, the study coordinator will query the EVOLV-Rx dashboard weekly
- The coordinator will ensure the presence of inclusion/exclusion criteria via chart review and using the EVOLV-Rx dashboard, they will then flag the patient if they are receiving hospice care and should be excluded from the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EVOLV-Rx dashboardUsing the TheraDoc® platform, the investigators will deploy a custom-designed EVOLV-Rx dashboard that incorporates all 18 components of the EVOLV-Rx metric. [Within TheraDoc®, the dashboard will display an automated report in the form of a patient list that includes the names, locations, and specific LVP practices to which Veterans under their care are subject. Pharmacists will then query specific patients on the list as part of their required medication review. The dashboard will provide detailed clinical decision support by identifying the specific EVOLV-Rx LVP criteria met by each flagged medication and provide access to the patient's full medication list, problem list, and laboratory or testing data contained within VISTA.] Pharmacists may use the EVOLV-Rx dashboard to track Veterans' receipt of LVP practices and quickly document actions related to the intervention, such as patient and family caregiver engagement, deprescribing LVP practices, or any other medications discontinued. | Other | Stepped Wedge |
Primary outcome
Count of Low-Value Practices (LVP) per 100 Veterans as per the EVOLV-rx metric
Time frame: Baseline (starting an average of one year prior to implementation of intervention) through study completion, average time frame of 3.25 years of observation
The primary effectiveness outcome is the count of LVP practices per 100 Veterans as per the EVOLV-Rx metric, which the investigators will consistently assess monthly from the start of the pre-implementation usual care phase through quarter 10. Data on LVP will be obtained from the VA Corporate Data Warehouse (CDW), including BCMA data, to fully capture Veterans' duration of medication use and pertinent diagnoses incorporated in the EVOLV-Rx criteria. A low-value medication will be characterized as discontinued if its discontinuation is sustained for 7 days, as this duration is unlikely to represent a temporary discontinuation of the medication. As per RE-AIM, maintenance will be determined via the assessment of the primary effectiveness outcomes at 6 and 12 months after the start of the intervention in each step of Community Living Centers (CLCs).
5 secondary outcomes
Average Count of Long-term medications
Time frame: Baseline (starting an average of one year prior to implementation of intervention) through study completion, average time frame of 3.25 years of observation
Proportion of Veterans with Polypharmacy and hyperpolypharmacy
Time frame: Baseline (starting an average of one year prior to implementation of intervention) through study completion, average time frame of 3.25 years of observation
Proportion of Veterans with Adverse drug reactions
Time frame: Baseline (starting an average of one year prior to implementation of intervention) through study completion, average time frame of 3.25 years of observation
Proportion of Veterans with Adverse drug withdrawal events
Time frame: Baseline (starting an average of one year prior to implementation of intervention) through study completion, average time frame of 3.25 years of observation
Average Count of emergency department (ED) visits/hospitalizations
Time frame: Baseline (starting an average of one year prior to implementation of intervention) through study completion, average time frame of 3.25 years of observation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Oct 2026.
- Results publication: PubMed 40991286Burke RE, Hutchins F, Heintz J, Patel SR, Appel S, Norman J, Gupta A, Rose L, Werner RM. Size of the Financial Incentives in Medicare's Skilled Nursing Facility Value-Based Purchasing Program. JAMA Netw Open. 2025 Sep 2;8(9):e2533369. doi: 10.1001/jamanetworkopen.2025.33369.
- Results publication: PubMed 40971164Rose L, Wagner TH. The Future of the VA-The Privatization Debate. JAMA Health Forum. 2025 Sep 5;6(9):e253183. doi: 10.1001/jamahealthforum.2025.3183.
- Individual participant dataSharing planned: No
Related trials for Low-Value Care
Recruiting
DE-RESTRICT: Deimplementing Activity Restriction for Preterm Birth Prevention
Preterm Birth, Activity Restriction
Active, not recruiting
Applying the Intention-Action Framework to Specialty Referrals
Cardiology, Gastroenterology
Not yet recruiting
Reduction of Low-value Prescribing Through Audit and Feedback
Inappropriate Prescribing, Implementation Science
Recruiting
A Personalised Approach Utilising the Frailty Index to Empower Consumers
Gastrointestinal Diseases
RecruitingObservational study
Low-value Care, and Variation in Practice for Children Hospitalized With Bronchiolitis
Bronchiolitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Thomas R Radomski, MD MS principal investigator
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing EVOLV-Rx dashboard in people with Low-Value Care, run by VA Office of Research and Development at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 14 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Count of Low-Value Practices (LVP) per 100 Veterans as per the EVOLV-rx metric (time frame: Baseline (starting an average of one year prior to implementation of intervention) through study completion, average time frame of 3.25 years of observation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07166107, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Oct 2026.